Larimar Therapeutics (LRMR) Free Cash Flow Growth (1y) (2014 - 2025)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Free Cash Flow Growth (1y) (2014 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 82.57% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 376.81% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 9.25% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -38.10% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 38.94% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 152.82% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 203.80% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 58.53% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 99.91% |
| Jun 30, 2025 | -36.21% |
| Mar 31, 2025 | -154.93% |
| Dec 31, 2024 | -130.67% |
| Sep 30, 2024 | -167.77% |
| Jun 30, 2024 | -93.07% |
| Mar 31, 2024 | -38.24% |
| Dec 31, 2023 | -43.17% |
| Sep 30, 2023 | -56.35% |
| Jun 30, 2023 | 1.46% |
| Mar 31, 2023 | 1.15% |
| Dec 31, 2022 | 15.83% |
| Sep 30, 2022 | 51.93% |
| Jun 30, 2022 | 30.34% |
| Mar 31, 2022 | 33.84% |
| Dec 31, 2021 | 22.69% |
| Sep 30, 2021 | -8.92% |
| Jun 30, 2021 | 11.91% |
| Mar 31, 2021 | -28.49% |
| Dec 31, 2020 | -29.31% |